Down Syndrome
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 38 trials with date data
Clinical Trials (38)
Total enrollment: 105,325 patients across 38 trials
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome
Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
AEF0217 in Participants With Down Syndrome
Down Syndrome Obstructive Sleep Apnea
Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Therapies for Down Syndrome Regression Disorder
A Study of ACI-24 in Adults With Down Syndrome
Tofacitinib for Immune Skin Conditions in Down Syndrome
A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome
AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome
Qualitative Effects of AEF0217 in Down Syndrome People
Role of Early Motor Experience in Infants With Down Syndrome
Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)
Impact of an Orthotic Garment on Gross Motor Skills for Infants With Down Syndrome
Assessment of Neural Oscillations in Adult Subjects With Down Syndrome and Typically Developing Subjects in Resting State and While Conducting Cognitive Tasks
Pulmonary Health in Children With Down Syndrome
Delivering Early Intervention to Children With Down Syndrome
Clinical Validation of the Bordeaux Maze Test
Evaluating Cognitive Outcomes in Down Syndrome
Storybook Reading in Individuals With Down Syndrome
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
The Human Trisome Project
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome
DS-Connect®: The Down Syndrome Registry
Down Syndrome Metabolic Health Study
Treatment Trial of Subclinical Hypothyroidism in Down Syndrome
Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite
Gait in Children With Down Syndrome While Wearing Orthoses
The Experience of Caregivers of Children With Down Syndrome
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.